Pharma News, April 2017 Highlights Pill

FavoriteLoadingAdd to favorites
  • USFDA issues Warning Letter To Divis Labs For Vishakhapatnam Unit
  • Sun Pharma Indirect Arm To Acquire Thallion Pharmaceuticals
  • Drug firm Cipla’s subsidiary in South Africa has completed the acquisition of Anmarate (Pty) Ltd, South Africa, a deal estimated at around ZAR 26 million.
  • India’s antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices. India’s Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.
  • NPPA squashed the request of two leading international stent manufacturers — Abbott and Medtronics — to withdraw their latest generation of stents from the Indian market. Government’s move to cap stent prices had upset international manufacturers who said it was not ‘commercially viable’ for them to sell the stents in the country at restricted prices.
  • The US Food and Drug Administration noted incomplete laboratory records, failure to create accurate duplicates of key records, and to properly investigate drug batches that didn’t meet specifications, among potential manufacturing violations FDA observed during an inspection of Sun Pharmaceutical Industries Ltd.’s Dadra unit, FDA called a Form 483.
  • Aurobindo Pharmahas received a Form 483 with six observations from United States Food and Drug Administration (US FDA) for its Unit-III formulation facility located at Bachupally in Hyderabad.All the observations are related to procedural improvements, the company said. “None of the observations are related to data integrity,” Aurobindo said in a statement to stock exchanges.
  • The Indian pharmaceutical sector is expected to see a slight fall in the exportvalue in FY17 due to price erosion and lack of any blockbuster drug
  • NPPA has issued preliminary notices to several pharmaceutical companies for 613 cases of over-charging. The office order said companies which had been found overcharging included Sun Pharmaceutical, Dr Reddy’s Laboratories, GlaxoSmithKline, Abbott, Alembic Pharmaceuticals, Intas Pharmaceutical, Sanofi, Torrent Pharmaceuticals, Zydus Cadila, Wockhardt, Cipla and Lupin, among others.
  • Intas Pharma has emerged as India’s most-valued privately-held pharmaceuticals company, at USD 3.5 billion (Rs 23,000 crore) following a private-equity transaction. A privately-held company is a firm that has less than 50 shareholders. Intas is among India’s top 10 pharma companies and has a 2.8 percent domestic market share.
  • A Body of major domestic pharma firms, IPA has hit out at the government over drug price control issue. In a letter written to Niti Aayog Vice-Chairman Arvind Panagariya, the IPA said the last couple of years have been unsettling for the domestic pharma industry due to “arbitrary and imaginative” implementation of the drug pricing policy.
  • NIPER to set up pharma products test lab in Baddi
  • Drug firm Torrent Pharmaceuticals on Tuesday said it has entered into pacts with Swiss pharma major Novartis AG to acquire certain generic drugs.
  • The sixth centralized Pharmacy Placement Fair of Gujarat Technological University (GTU) was attended by 530 students on the first day. A total of 30 companies participated in the campus placement.
  • PMO wants drug pricing NPPA and departments of pharmaceuticals move to the Union ministry of health and family welfare from the ministry of chemicals and fertilizers

Leave a Comment

Your email address will not be published. Required fields are marked *